MAM
Dwight ‘Mitch’ Barns will be new Nielson CEO
MUMBAI: World known media measurements and ratings company Nielson has found a replacement for current CEO David Calhoun who is set to step down on 1 January 2014. Dwight ‘Mitch’ Barns will take over the reins from Calhoun who will take the role of executive chairman. Barns is currently global client service president.
 |
Barns has been in the company from the past 16 years while Calhoun has been CEO since 2006 when he joined the company. Prior to this Calhoun had been with General Electric for 26 years. As exec chairman he will be a guide to Barns and other executives. He will also remain a substantial owner of Nielson equity purchased and earned by him while he was the CEO.
Barns has held positions of Nielson’s US TV ratings business and president of greater China region. Before Nielson, he was with Proctor & Gamble for 12 years. Calhoun helped Nielson turn from a privately held firm to a publicly traded company overseeing its IPO (Initial Public Offer) in 2011.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
